Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
The studies that have been conducted have shown that people with T1D who are overweight or obese have the most benefits from the GP1 agonist category of medications
The drug causes thyroid cancer in rodents, but the risk to humans is unknown
For NHS patients, Tier 3 weight management services may offer access to these medications alongside intensive lifestyle support, though availability varies by region
Whilst Phase 2 trial results are promising, retatrutide has not yet received MHRA or EMA approval and remains available only within authorised clinical trials
+ Earn Up to 8X Points Aug
US$ 26.13
US$ 26.32
US$ 20.28
